Skip to content
Disclosery

Ghost Tree Capital, LLC

Follow

13F filer, CIK 1595851, NEW YORK, NY

Ghost Tree Capital, LLC reported $304,065,997 across 69 holdings for the quarter ended 2023-09-30, in a 13F-HR filed 2023-11-14. Its ten largest share positions make up 43.1% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-23-002080

Period
2023-09-30
Reported value
$304M
Holdings
69
Top 10 weight
43.1%
New
27
Sold out
15

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KRYSadded+60,000$6.96M
IMVTnew+130,000$4.99M
TARSadded+250,000$4.44M
TSHAnew+1,325,000$4.19M
DECIPHERA PHARMACEUTICALS INnew+325,000$4.13M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
APLSexited-180,000-$16.4M
AKROreduced-245,000-$12.4M
REATA PHARMACEUTICALS INCexited-85,000-$8.67M
PCVXreduced-140,000-$7.14M
AMLXreduced-335,000-$6.13M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2023

Share positions as resolved from 13F-HR 0001420506-23-002080, largest first. % of portfolio is the value over $206,522,308, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 195,000 shares; 2023Q2: 330,000 shares; 2023Q3: 330,000 shares 330,000$18.8M9.11%0Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 20,000 shares; 2023Q3: 80,000 shares 80,000$9.28M4.49%+60,000Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 20,000 shares; 2023Q1: 30,000 shares; 2023Q2: 55,000 shares; 2023Q3: 57,500 shares 57,500$8.4M4.07%+2,500Timeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,100,000 shares; 2023Q2: 825,000 shares; 2023Q3: 1,000,000 shares 1,000,000$8.36M4.05%+175,000Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 130,000 shares; 2023Q1: 110,000 shares; 2023Q2: 100,000 shares; 2023Q3: 85,000 shares 85,000$7.96M3.85%-15,000Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 235,000 shares; 2023Q1: 225,000 shares; 2023Q2: 110,000 shares; 2023Q3: 110,000 shares 110,000$7.69M3.72%0Timeline
ALPINE IMMUNE SCIENCES INCALPINE IMMUNE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 200,000 shares; 2023Q2: 347,432 shares; 2023Q3: 664,132 shares 664,132$7.6M3.68%+316,700
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 160,000 shares; 2023Q1: 225,000 shares; 2023Q2: 280,000 shares; 2023Q3: 140,000 shares 140,000$7.14M3.46%-140,000Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 80,000 shares; 2023Q1: 80,000 shares; 2023Q2: 150,000 shares; 2023Q3: 400,000 shares 400,000$7.11M3.44%+250,000Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 225,000 shares; 2023Q2: 225,000 shares; 2023Q3: 400,000 shares 400,000$6.67M3.23%+175,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 800,000 shares; 2023Q1: 550,000 shares; 2023Q2: 575,000 shares; 2023Q3: 650,000 shares 650,000$6.34M3.07%+75,000Timeline
AMBRX BIOPHARMA, INC. SPONS…AMBRX BIOPHARMA, INC. SPONSORED A…Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 250,000 shares; 2023Q2: 238,225 shares; 2023Q3: 525,000 shares 525,000$6.04M2.92%+286,775
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 85,000 shares; 2023Q1: 275,000 shares; 2023Q2: 360,000 shares; 2023Q3: 115,000 shares 115,000$5.82M2.82%-245,000Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 130,000 shares 130,000$4.99M2.42%newTimeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 55,000 shares; 2023Q1: 60,000 shares; 2023Q2: 85,000 shares; 2023Q3: 40,000 shares 40,000$4.85M2.35%-45,000Timeline
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 280,981 shares; 2023Q3: 705,881 shares 705,881$4.33M2.1%+424,900Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 165,000 shares; 2023Q1: 175,000 shares; 2023Q2: 240,000 shares; 2023Q3: 275,000 shares 275,000$4.22M2.04%+35,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 1,325,000 shares 1,325,000$4.19M2.03%newTimeline
DECIPHERA PHARMACEUTICALS INDECIPHERA PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 325,000 shares 325,000$4.13M2%new
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 154,250 shares; 2023Q3: 395,000 shares 395,000$4.1M1.98%+240,750Timeline
REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 250,000 shares; 2023Q2: 525,000 shares; 2023Q3: 350,000 shares 350,000$4.01M1.94%-175,000
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 350,000 shares; 2023Q1: 475,000 shares; 2023Q2: 550,000 shares; 2023Q3: 215,000 shares 215,000$3.94M1.91%-335,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 200,000 shares; 2023Q2: 185,000 shares; 2023Q3: 98,951 shares 98,951$3.38M1.64%-86,049Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 101,443 shares 101,443$3.02M1.46%newTimeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 150,000 shares; 2023Q1: 325,000 shares; 2023Q2: 350,000 shares; 2023Q3: 200,000 shares 200,000$2.9M1.41%-150,000Timeline
IMMUNOGEN INCIMMUNOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 124,977 shares; 2023Q2: 100,000 shares; 2023Q3: 175,000 shares 175,000$2.78M1.34%+75,000
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 55,000 shares 55,000$2.77M1.34%newTimeline
AEROVATE THERAPEUTICS INCAEROVATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 135,000 shares; 2023Q1: 200,000 shares; 2023Q2: 201,197 shares; 2023Q3: 201,197 shares 201,197$2.73M1.32%0
MORPHOSYS AGMORPHOSYS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 400,000 shares 400,000$2.69M1.3%new
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 90,000 shares 90,000$2.65M1.28%newTimeline
MIRATI THERAPEUTICS INCMIRATI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 200,000 shares; 2023Q1: 140,000 shares; 2023Q2: 200,000 shares; 2023Q3: 60,000 shares 60,000$2.61M1.27%-140,000
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 325,000 shares 325,000$2.6M1.26%newTimeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 600,000 shares; 2023Q2: 650,000 shares; 2023Q3: 225,000 shares 225,000$2.49M1.21%-425,000Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 450,000 shares; 2023Q1: 450,000 shares; 2023Q2: 300,173 shares; 2023Q3: 300,000 shares 300,000$2.24M1.08%-173
FOLDAMICUS THERAPEUTICQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 475,000 shares; 2023Q2: 200,000 shares; 2023Q3: 175,000 shares 175,000$2.13M1.03%-25,000Timeline
KARUNA THERAPEUTICS INCKARUNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 40,000 shares; 2023Q1: 17,500 shares; 2023Q2: 12,500 shares; 2023Q3: 12,500 shares 12,500$2.11M1.02%0
ACELYRIN INCACELYRIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 200,000 shares 200,000$2.03M0.98%new
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 100,000 shares; 2023Q3: 100,000 shares 100,000$2.01M0.97%0Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 25,000 shares; 2023Q2: 42,000 shares; 2023Q3: 75,000 shares 75,000$1.98M0.96%+33,000Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 80,000 shares 80,000$1.67M0.81%newTimeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 22,500 shares 22,500$1.51M0.73%newTimeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 375,000 shares; 2023Q2: 215,000 shares; 2023Q3: 215,000 shares 215,000$1.44M0.7%0Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 75,000 shares; 2023Q2: 75,000 shares; 2023Q3: 75,000 shares 75,000$1.35M0.65%0Timeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 150,000 shares 150,000$1.34M0.65%newTimeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 2,500 shares 2,500$1.23M0.6%newTimeline
VTYXVENTYX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 35,000 shares 35,000$1.22M0.59%newTimeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 90,000 shares; 2023Q1: 150,000 shares; 2023Q2: 250,000 shares; 2023Q3: 250,000 shares 250,000$1.21M0.59%0Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 100,000 shares 100,000$963K0.47%newTimeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 120,000 shares; 2023Q2: 190,000 shares; 2023Q3: 65,000 shares 65,000$894K0.43%-125,000Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 64,000 shares; 2023Q3: 64,000 shares 64,000$748K0.36%0Timeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 110,000 shares; 2023Q3: 45,000 shares 45,000$734K0.36%-65,000
INHIBRX INCINHIBRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 35,000 shares; 2023Q3: 35,000 shares 35,000$642K0.31%0
FUSION PHARMACEUTICALS INCFUSION PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 350,000 shares; 2023Q2: 412,699 shares; 2023Q3: 243,287 shares 243,287$633K0.31%-169,412
ABOSACUMEN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 150,000 shares 150,000$622K0.3%newTimeline
89BIO INC89BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 200,000 shares; 2023Q2: not reported; 2023Q3: 30,000 shares 30,000$463K0.22%new
RNAMAVIDITY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 100,000 shares; 2023Q1: 125,000 shares; 2023Q2: 65,000 shares; 2023Q3: 65,000 shares 65,000$415K0.2%0Timeline
RAIN ONCOLOGY INCRAIN ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 250,000 shares; 2023Q2: 325,000 shares; 2023Q3: 325,000 shares 325,000$280K0.14%0
Mersana Therapeutics IncMersana Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 61,250 shares; 2023Q3: 61,250 shares 61,250$77.8K0.04%0

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
XBISPDR SERIES TRUST S&P BIOTECHcall300,000$21.9M0
SRPTSAREPTA THERAPEUTICS INC COMcall150,000$18.2Mnew
MLTXMOONLAKE IMMUNOTHERAPEUTICS Stockput250,000$14.2Mnew
AKROAKERO THERAPEUTICS INC COMcall250,000$12.6Mnew
APLSAPELLIS PHARMACEUTICALS INC COMcall185,000$7.04Mnew
RCKTROCKET PHARMACEUTICALS INC COMcall295,000$6.04Mnew
SNDXSYNDAX PHARMACEUTICALS INC COMput300,000$4.36Mnew
REPLREPLIMUNE GROUP INC COMMON STOCKcall250,000$4.28Mnew
CYMABAY THERAPEUTICS INCCYMABAY THERAPEUTICS INC COMcall237,900$3.55Mnew
IMVTIMMUNOVANT INC COMput85,000$3.26Mnew
ACELYRIN INCACELYRIN INC COMput200,000$2.03Mnew

Sold out in Q3 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
APLSAPELLIS PHARMACEUTICALS INC180,000$16.4Mshares
REATA PHARMACEUTICALS INCREATA PHARMACEUTICALS INC85,000$8.67Mshares
INCYINCYTE CORP65,000$4.05Mshares
ONCBEONE MEDICINES LTD22,500$4.01Mshares
VIRVIR BIOTECHNOLOGY INC150,000$3.68Mshares
RCKTROCKET PHARMACEUTICALS INC75,000$1.49Mshares
BCRXBIOCRYST PHARMACEUTICALS INC200,000$1.41Mshares
MORPHIC HLDG INCMORPHIC HLDG INC20,000$1.15Mshares
BIOXCEL THERAPEUTICS INCBIOXCEL THERAPEUTICS INC130,000$866Kcall
SPRINGWORKS THERAPEUTICS INCSPRINGWORKS THERAPEUTICS INC27,578$723Kshares
IOVAIOVANCE BIOTHERAPEUTICS INC100,000$704Kshares
PTCTPTC THERAPEUTICS INC16,675$678Kshares
REPLREPLIMUNE GROUP INC10,865$252Kshares
VNDAVANDA PHARMACEUTICALS INC31,000$204Kshares
FIBROGEN INCFIBROGEN INC36,500$98.5Kshares

How Q3 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-23-002080 base2023-11-14acceptance time not in the bulk data set